Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Colorectal Cancer
Cologuard: Stool DNA Test Performs Well in Community-Based Setting Among Medicare Beneficiaries
By
Charles Bankhead
Colorectal Cancer
,
Solid Tumors
July 2016, Vol 7, No 6
The multitarget stool DNA test, a noninvasive screening tool for colorectal cancer (CRC), demonstrated potential for identifying cancer and advanced adenomas in community-based individuals who had previously not followed national screening recommendations, reported Mark Prince, MD, MBA, Director of Gastroenterology, USMD Health System, Arlington, TX, at the 2016 American Association for Cancer Research annual meeting.
Read Article
Biomarker Panel May Aid Early Detection of Colorectal Cancer
By
Charles Bankhead
Colorectal Cancer
,
Personalized Medicine
,
Solid Tumors
March 2016, Vol 7, No 2
A panel of 4 blood-derived biomarkers showed promise as an aid to early detection of colorectal cancer (CRC). The panel yielded a negative predictive value exceeding 90% for CRC, the combination of CRC and high-risk adenomas, and colorectal plus other cancers. The biomarker assay demonstrated fair to good performance characteristics, associated with the receiver operating characteristic (ROC) curve ranging between 0.70 and 0.80.
Read Article
Aprepitant Improves Emesis Control in Patients with Colorectal Cancer
Colorectal Cancer
,
GI Cancers
November 2015, Vol 6, No 10
Barcelona, Spain—Controlling and minimizing nausea and vomiting enables patients with cancer to continue their chemotherapy. A clinical trial reported at the 2015 European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer shows that the newly approved agent aprepitant (Emend), an oral neurokinin (NK)
1
antagonist, improved antiemetic control in patients with colorectal cancer (CRC) who were receiving oxaliplatin-based chemotherapy, according to Junichi Nishimura, MD, Assistant Professor, Osaka University, Japan.
Read Article
In the Real World, Bevacizumab Improves Survival in Patients with Metastatic Colorectal Cancer
By
Wayne Kuznar
Colorectal Cancer
April 2014, Vol 5, No 3
San Francisco, CA—In routine patient care, adding bevacizumab (Avastin) to standard FOLFIRI (leucovorin, 5-fluorouracil, and irinotecan) improves progression-free survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer (mCRC), according to data presented at the 2014 Gastrointestinal Cancers Symposium.
Read Article
Adenoma Detection Rates in Colonoscopy: The Higher the Better
By
Caroline Helwick
Colorectal Cancer
,
Personalized Medicine
July 2013, Vol 4, No 6
Orlando, FL—In screening colonoscopies, high adenoma detection rates (ADRs) by physicians are associated with fewer missed cancers and with better survival from colorectal cancer (CRC), according to 2 studies presented at Digestive Disease Week 2013.
Read Article
Future of Colorectal Cancer Therapy: Novel Targeted Pathways
By
Caroline Helwick
Colorectal Cancer
,
Genitourinary Cancers Symposium
April 2011, Vol 2, No 2
Read Article
Competing Tests for Colorectal Cancer Risk Recurrence
By
Caroline Helwick
Colorectal Cancer
,
Genitourinary Cancers Symposium
April 2011, Vol 2, No 2
Read Article
Individualizing Colorectal Cancer Care through Genetics
Annual ONS Congress
,
Colorectal Cancer
,
Personalized Medicine
July/August 2010, Vol 1, No 3
Read Article
New Colorectal Cancer Therapies Foster New Discussions on the Value of Medications
Colorectal Cancer
May 2010, Vol 1, No 1
New chemotherapies for metastatic colon cancer have improved life expectancy, but at a significant cost, say the authors of a study that explores the value of medications including bevacizumab (Avastin, Genentech), capecitabine (Xeloda, Roche Laboratories), cetuximab (Erbitux, Bristol-Myers Squibb), irinotecan hydrochloride (Camptosar, Pfizer, Inc), and oxaliplatin (Eloxatin, Sanofi-Aventis LLC).
Read Article
Page 2 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma